NOVABIO Research Profile

What Is Elamipretide (SS-31)?

Elamipretide (SS-31) is a mitochondria-targeted peptide identified by the Elamipretide and SS-31 names. This page identifies the material as SS-31 Elamipretide, with amino acid count 4; synonyms SS-31. The Elamipretide (SS-31) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identitySS-31 Elamipretide
Available specifications10mg, 20mg, 50mg
Evidence snapshot2 trials · 287 publications
Last verified2026-10-06

What Is Elamipretide (SS-31)?

Elamipretide (SS-31) is a mitochondria-targeted peptide identified by the Elamipretide and SS-31 names. This page identifies the material as SS-31 Elamipretide, with amino acid count 4; synonyms SS-31. The Elamipretide (SS-31) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

2ClinicalTrials.gov query records
287PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Elamipretide (SS-31) is organized around mitochondrial peptide research, membrane-interaction studies, peptide characterization, and analytical peptide workflows. For Elamipretide (SS-31), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT05168774FRDA Investigator Initiated Study (IIS) With ElamipretidePhase 1/Phase 2CompletedFriedreich Ataxia2025-12-12
NCT05194631Evaluation of the Regeneration Capacity of Satellite Cells From the Quadriceps Compared to That of the DiaphragmNACompletedDiaphragm Injury, Mechanical Ventilation Complication2024-12-06

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.

Journal of neuroinflammation · 2019 Nov 20

PMID 31747905
Selected PubMed record

SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 Feb

PMID 39848110
Selected PubMed record

Mitochondrial disorders leading to Alzheimer's disease-perspectives of diagnosis and treatment.

GeroScience · 2024 Jun

PMID 38457008
Selected PubMed record

Elamipretide (SS-31) treatment attenuates age-associated post-translational modifications of heart proteins.

GeroScience · 2021 Oct

PMID 34480713
Selected PubMed record

Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.

Antioxidants (Basel, Switzerland) · 2023 Nov 21

PMID 38136142
Selected PubMed record

Drug repurposing in Alzheimer's disease: Emerging therapeutic strategies and promising candidates.

Ageing research reviews · 2026 Jun

PMID 41956136

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
SS-31 Elamipretide
Available Specifications
10mg, 20mg, 50mg
Pack Format
10 Vials
CAS Number
736992-21-5
Molecular Formula
C32H49N9O5
Molecular Weight
639.8 g/mol
Amino Acid Count
4
Sequence
D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2',6'-dimethyl-L-tyrosine)
Synonyms
SS-31
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 11764719 · Product form must still be matched to the catalogue and batch record.

Research Tools for Elamipretide (SS-31)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Elamipretide (SS-31) Research Summary

Identity

SS-31 Elamipretide; specifications: 10mg, 20mg, 50mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Elamipretide (SS-31) is organized around mitochondrial peptide research, membrane-interaction studies, peptide characterization, and analytical peptide workflows. For Elamipretide (SS-31), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

2 registry records and 287 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Elamipretide (SS-31) is represented here by the catalogue identity SS-31 Elamipretide. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg, 20mg, 50mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Elamipretide (SS-31) is organized around mitochondrial peptide research, membrane-interaction studies, peptide characterization, and analytical peptide workflows. For Elamipretide (SS-31), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 2 ClinicalTrials.gov records and 287 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Elamipretide (SS-31) FAQ

What is Elamipretide (SS-31)?

Elamipretide (SS-31) is a mitochondria-targeted peptide identified by the Elamipretide and SS-31 names. This page identifies the material as SS-31 Elamipretide, with amino acid count 4; synonyms SS-31. The Elamipretide (SS-31) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Elamipretide (SS-31)?

The synchronized query returned 2 ClinicalTrials.gov records and 287 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Elamipretide (SS-31) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.